Arrowhead Research Corp.


Company Update (NASDAQ:ARWR): Arrowhead Research Corp eports Fiscal 2016 First Quarter Results

Arrowhead Research Corp (NASDAQ:ARWR) announced financial results for its fiscal 2016 first quarter endedDecember 31, 2015. Fiscal 2016 First Quarter and Recent Company …

Company Update (NASDAQ:ARWR): Arrowhead Research Corp’s ARC-AAT Granted EMA Orphan Drug Designation

Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to …

Stock Update (NASDAQ:ARWR): Arrowhead Research Corp Begins Dosing the Phase 2b MONARCH Combination Study of ARC-520 in Patients with Chronic Hepatitis B Infection

Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, dosed the first patient in the Phase 2b MONARCH combination study of ARC-520, …

Looking Ahead of Wall Street: Arrowhead Research Corp (ARWR), Oracle Corporation (ORCL), and BlackBerry Ltd (BBRY)

Holiday shopping and festivities are in full swing, but several companies are slated to report earnings this week ahead of the holidays. Here’s what …

Analysts Weigh In on Two Healthcare Stocks: Arrowhead Research Corp (ARWR), ZIOPHARM Oncology Inc. (ZIOP)

Two clinical stage biopharmaceutical companies, Arrowhead Research Corp (NASDAQ:ARWR) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), both provided a data update on pipeline drugs.

Company Update (NASDAQ:ARWR): Arrowhead Research Corp’s ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B Infection

Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presented data at HEP DART 2015 showing that in chronically HBV-infected chimpanzees treated …

Monday Morning’s Market Insights: bluebird bio Inc (BLUE), Chipotle Mexican Grill, Inc. (CMG), Seadrill Ltd (SDRL), Arrowhead Research Corp (ARWR)

bluebird bio Inc (NASDAQ:BLUE) plummeted more than 30% this morning down to $58 as the company presented disappointing BB305 data at the American …

Stock Update (NASDAQ:ARWR): Arrowhead Research Corp Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA

Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presented data from a Phase 2a clinical study at The AASLD Liver Meeting …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts